Stifel reiterates Altria stock Buy rating on smokeable strength By Investing.com

Stifel reiterated a Buy on Altria with a $68 price target; Altria trades at a P/E of 12.7 and reported a Smokeable gross margin of 82.7%. Stifel expects 2026 EPS growth of 2.5%–5.5% and maintains an EPS estimate of $5.62 (~3.5% growth), while the company yields 5.7% and has raised dividends for 8 consecutive years. Altria is rolling out the on! PLUS nicotine pouch nationally with introductory pricing to drive trial; e-vapor and heated tobacco are medium-term opportunities. British American Tobacco posted H2 2025 group revenue up 2.1% and adjusted profit up 3.4% (top end of guidance), though shares dipped slightly pre-market.

Analysis

Incumbent US tobacco operators retain a structural advantage from national distribution, scale manufacturing and captive retail relationships — that advantage amplifies when new oral-nicotine formats require rapid national merchandising and SKU cutovers. The second-order beneficiaries are contract packagers, specialty cellulose/pouch suppliers and logistics providers that can scale SKU proliferation quickly; smaller international peers without those US channels will find it costly and slow to respond, creating a 12–24 month window to consolidate retail shelf share.

Near-term P&L dynamics will be driven by two mechanical levers: promotional intensity and trial-to-repeat conversion. Expect introductory pricing to knock 100–200bp off gross margins in the first 6–9 months in markets with heavy promos; if repeat rates exceed ~30% within 9–12 months the margin erosion reverts and unit economics improve materially. Regulatory shocks (FDA guidance changes, state excise tweaks) are binary catalysts that can compress valuation multiples within 3–9 months if they limit flavors/marketing or raise effective taxes.

For relative performance, US-focused names with heavy cash-return programs are insulated versus geographically diverse peers exposed to lower-growth EM markets; however, that insulation is contingent on stabilizing smokeable volume declines. If cigarette declines accelerate beyond current secular trends (driven by younger cohorts or accelerated flavor restrictions), even cash-heavy firms will see EPS downgrades over a 2–4 year horizon, making multi-year call buying a higher-beta bet than owning the shares outright.

The consensus appears to underweight execution risk on commercial scaling and overestimate near-term margin recovery. A fast competitive response or regulatory pushback would flip the narrative quickly; conversely, sustained above-30% trial-to-repeat would be an underappreciated upside that could drive a re-rate over 12 months.

Key Decisions for Investors

• Long MO (equity) sized as a tactical overweight — 6–12 month horizon. Target 20–30% upside if trial conversion >30% and promotional drag fades; hard stop 12–15% to protect against unexpected regulatory headlines.
• Pair trade: Long MO / Short BTI — 6–12 months to isolate US pouch adoption vs global cigarette exposure. Expect relative outperformance of 10–25% if US commercialization succeeds; risk is symmetric if regulatory limits roll through both markets.
• Buy MO 9–12 month call spread (debit-limited) to capture upside while capping premium decay — cost < full delta exposure, payoff 2–4x if share re-rate. Use spread width to define acceptable max loss and take profits if MO rallies >25% within 6 months.
• Income overlay: sell 1–3 month covered calls on existing MO position to monetize near-term implied volatility and fund trial-period margin risk. Aggressive premiums can add 2–4% quarterly yield but cap upside if a rapid re-rate occurs.
• Event hedge: buy short-dated puts on MO (6–9 week) sized to cover material headline risk around regulatory announcements; treat as insurance — small premium relative to equity exposure but limits tail downside from unexpected policy moves.